



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 16th April 2018

Re: Freedom of Information Request
Ref: 55- 2018

Thank you for your email dated the 26th March 2018, requesting information regarding patient treatment figures.

For information requested, please see Appendix 1

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could

take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>

Appendix 1

Within your Trust in the last 3 months – latest that you have available;

Question 1 - In the past three months, how many metastatic hepatocellular carcinoma patients were treated with:

Version: 1.0
Ref: ECGMFOIRE

Sorafenib (Nexavar)	24	
Other active systemic anti-cancer therapy	4	
	Cisplatin + Gemcitabine (D 1 & 8)	1
	MTL-CEBPA	1
	Pembrolizumab	2
Other including palliative care	1	
	CCC Specialist Palliative care team as Inpatient or Outpatient only	1

Question 2 - In the past three months, how many metastatic renal cell carcinoma patients were treated with:

**Patients may fall into more than one cohort (have had multiple regimes).*

Sunitinib (Sutent)	18	
Pazopanib (Votrient)	33	
Everolimus (Afinitor)	0	
Temsirolimus (Torisel)	0	
Cabozantinib (Cometriq)	13	
Nivolumab (Opdivo)	30	
Axinitib (Inlyta)	5	
Nivolumab + Ipilimumab (Opdivo + Yervoy)	0	
Levantinib (Lenvima) + Everolimus (Afinitor)	0	
Tivozanib (Fotivda)	0	
Other active systemic anti-cancer therapy	11	
	Gemcarbo	1
	Cisplatin & Gemcitabine	2
	Pembrolizumab	4
	IMmotion151 Trial	4
Other including palliative care	22	
	CCC Specialist Palliative care team as Inpatient or Outpatient only	2
	1 st Intervention Specialist Palliative care team only (not CCC)	1
	Palliative Radiotherapy only	11
	Denosumab only	5
	Zoledronate only	1
	Lanreotide only	1
	Provera only	1

Question 3 - In the past 3 months, how many metastatic melanoma patients were treated with:

**Patients may fall into more than one cohort (have had multiple regimes).*

Skin Melanoma

Pembrolizumab (Keytruda)	33
Nivolumab (Opdivo)	24

Ipilimumab (Yervoy)	14	
Nivolumab + Ipilimumab (Opdivo + Yervoy)	1	
Dabrafenib + Trametinib (Tafinlar + Mekinist)	10	
Dabrafenib (Tafinlar)	3	
Vemurafenib (Zelboraf)	0	
Vemurafenib + cobimetinib (Zelboraf + Cotellic)	0	
Other active systemic anti-cancer therapy	2	Trametinib 1 Amgen 201201325 T-Vec Trial 1
Other including palliative care	2	CCC Specialist Palliative care team as Inpatient or Outpatient only 2

Uveal Melanoma

Pembrolizumab (Keytruda)	10	
Nivolumab (Opdivo)	2	
Ipilimumab (Yervoy)	4	
Nivolumab + Ipilimumab (Opdivo + Yervoy)	1	
Dabrafenib + Trametinib (Tafinlar + Mekinist)	0	
Dabrafenib (Tafinlar)	0	
Vemurafenib (Zelboraf)	0	
Vemurafenib + cobimetinib (Zelboraf + Cotellic)	0	
Other active systemic anti-cancer therapy	11	IMCgp100 102-IMCgp100 3 IMCgp100-102 1 SELPAC(A) Trial - SELUMETINIB 1 SELPAC(C) Trial - PACLITAXEL 80 3 SELPAC(C) Trial - SELUMETINIB 2 SELPAC Trial - PACL SELUMETINIB 1
Other including palliative care	1	CCC Specialist Palliative care team as Inpatient or Outpatient only 1